Cadherin 17 is related to recurrence and poor prognosis of cytokeratin 19-positive hepatocellular carcinoma

Chao Wei Lee, Sey En Lin, Hsin I. Tsai, Po Jung Su, Chia Hsun Hsieh, Yung Chia Kuo, Chang Mu Sung, Cheng Yu Lin, Chi Neu Tsai, Ming Chin Yu

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


A previous study demonstrated that cytokeratin 19 (CK19) expression in hepatocellular carcinoma (HCC) is an indicator of HCC invasiveness, including lymph node metastasis (LNM), tumor infiltration/non‑encapsulation and poor prognosis. The exact mechanism by which CK19 expression results in poor prognosis remains unclear. Through the use of an Affymetrix U133A oligonucleotide microarray [20 patients with hepatitis B virus (HBV)-HCC], it was demonstrated that cadherin 17 (CDH17) significantly correlated with CK19 expression (R2, 0.867; P10% and CDH17 expression were independent prognostic factors for disease free survival (P=0.010 and 0.002, respectively). In vitro studies showed that epidermal growth factor can induce the expression of both CK19 and CDH17, and CDH17 in turn can enhance the expression of CK19 in HCC. In summary, this study demonstrated that the early recurrence and poor prognosis of CK19(+) HCC may be due to the expression of CDH17, a gene known to be associated with vascular invasion, tumor metastasis, and advanced tumor stage of HCC. Thus, novel therapeutics by targeting CDH17 may be beneficial for CK19(+) HCC.

Original languageEnglish
Pages (from-to)559-567
Number of pages9
JournalOncology Letters
Issue number1
Publication statusPublished - Jan 2018


  • Cadherin 17
  • Cytokeratin 19
  • Hepatocellular carcinoma
  • Hepatoma
  • Keratin 19
  • Prognosis
  • Recurrence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cadherin 17 is related to recurrence and poor prognosis of cytokeratin 19-positive hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this